Freeline Therapeutics Holdings PLC reports results for the quarter ended in March - Earnings Summary

Freeline Therapeutics Holdings

17/05/2021 22:41

* Freeline Therapeutics Holdings PLC  FRLN.OQ  reported a
quarterly adjusted loss of 98 cents​​ per share for the quarter
ended in March. The mean expectation of five analysts for the
quarter was for a loss of 78 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Freeline Therapeutics Holdings PLC's reported EPS for the
quarter was a loss of 98 cents​.
* The mean earnings estimate of analysts had fallen by
about 7.2% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Freeline Therapeutics Holdings PLC shares had fallen by 28.9%
this quarter and lost 52.1% so far this year.
* The company reported a quarterly loss of $34.95 million.
* Wall Street's median 12-month price target for Freeline
Therapeutics Holdings PLC is $25.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 17 at 09:40 p.m. GMT.
​All figures in US dollars